Avinger Cultura da Companhia

Mr. Himanshu N. Patel has been the Chief Technology Officer at Avinger, Inc. since October 2013 and previously served in the same position from January 2011 to November 2011. As Chief Technology Officer, Mr. Patel brings over 25 years of design experience developing medical devices, primarily for cardiovascular and peripheral artery disease treatment. He has extensive experience leading R&D and manufacturing operations across several companies. Mr. Patel holds a B.S. in Mechanical Engineering from M.S. University of Baroda, India and an M.S. in Mechanical Engineering from the University of Florida.

Mr. Matthew B. Ferguson, also known as Matt, has been the Chief Financial Officer and Chief Business Officer at Avinger, Inc. since January 2011. Mr. Ferguson served as the Chief Financial Officer of Tethys Bioscience, Inc. He has a successful track record in the financial management of growth-stage life sciences and technology businesses. He served as the Chief Financial Officer of Onyx Therapeutics, Inc., (alternate name Proteolix, Inc.,) since February 2008. He served as the Chief Financial Officer of Foxhollow Technologies Inc. since January 2004. He served as the Principal Accounting Officer of Foxhollow Technologies Inc. and also served as its Vice President of Finance. He served as Vice President of Finance and Business Development at Foxhollow Technologies Inc. from July 2002 to January 2004. He was responsible for Foxhollow Technologies Inc.'s 2004 initial public offering and played a significant role in its 2007 merger with ev3 Inc. He held a variety of financial management and business development positions at ChannelPoint Inc., from February 1998 to January 2002, including Director of Finance, Director of Corporate Development and Director of Sales Operations. He also served at Hewlett-Packard. He holds a B.S. in Civil Engineering from Stanford University, an M.S. in Mechanical Engineering from the University of Pennsylvania and an M.B.A. from the University of California at Berkeley.

Dr. John Bush Simpson, Ph.D., M.D., founded Avinger, Inc. in March 2007 and served as its Chief Executive Officer from march 2007 to December 2014. Dr. Simpson has been a Partner at Cardiovascular Medicine and Coronary Interventions, a cardiology physician group Since 1983. Dr. Simpson served as Scientific Advisor of Cryovascular Systems, Inc. He served as Managing Director of De Novo Ventures funds in fund complex. He was the Founder of Sawtooth Labs, Inc. He served as Clinical Director at De Novo Ventures. He served as the Chief Scientist of ev3, Inc. until February 7, 2008. He founded Foxhollow Technologies, Inc. and served as its Chief Executive Officer since June 5, 2006. He served as an Interim Chief Executive Officer of Foxhollow Technologies, Inc. from January 1, 2006 to June 5, 2006. From October 1996 to July 1997, he served as the President of Foxhollow Technologies Inc. He served as an Executive Chairman of Avinger, Inc. since December 2014 until December 11, 2017. He co founded LuMend, Inc. in 1996 and served as its Chairman of the Board. He is a co-owner of GIGL Investments L.P. He served as Chairman of the Board of Foxhollow Technologies, Inc. until January 1, 2006. In 1984, he founded Devices for Vascular Intervention, Inc. He founded several other interventional cardiology companies, included Vascular Intervention and Advanced Cardiovascular Systems. He founded and served as the Chairman of Perclose Inc. since inception in March 1992. He served as Vice Chairman at ev3, Inc. until February 7, 2008. He served as the Chairman of Avinger, Inc. since March 2007 until December 11, 2017. He served as Executive Director of Foxhollow Technologies Inc. since September 1996. He served as a Director of ev3, Inc. until February 7, 2008. He served as a Director of Perclose Inc. since inception in March 1992. He served as a Director of LuMend, Inc. He is a professor of clinical medicine at Stanford University. He served as a Staff Cardiologist at Sequoia Hospital in Redwood City, California since 1981. He has published extensively on a wide variety of topics pertaining to interventional cardiology and has lectured on various subjects throughout the world. He has been honored with the Andreas Greuntzig Award from the European Cardiology Society, received the Duke University Alumni Award and the Lifetime Achievement Award from the Trans Catheter Therapeutics Conference. He holds M.D. from the Duke University School of Medicine and completed a fellowship in interventional cardiology at Stanford University. He holds Ph.D. and M.S. in Biomedical Science from the University of Texas at Houston and an undergraduate degree B.S. in Agriculture from Ohio State University.

Corey Gibbs serves as the Vice President - US Sales of Avinger Inc.. Corey started at Avinger Inc. in August of 2013. Corey currently resides in Houston, Texas Area.

Jaafer Golzar serves as the Chief Medical Officer of Avinger Inc.. Jaafer started at Avinger Inc. in July of 2018. Jaafer currently resides in Greater Chicago Area.

Patty Hevey serves as the Vice President of Clinical & Regulatory Affairs of Avinger Inc.. Patty currently resides in the San Francisco Bay Area.